The process of developing new drugs is both time-consuming and costly, often taking over a decade and billions of dollars to obtain regulatory approval. Additionally, the complexity of patent protection for novel compounds presents challenges for pharmaceutical innovation. Drug repositioning offers an alternative strategy to uncover new therapeutic uses for existing medicines. Previous repositioning models have been limited by their reliance on homogeneous data sources, failing to leverage the rich information available in heterogeneous biomedical knowledge graphs. We propose HeteroKGRep, a novel drug repositioning model that utilizes heterogeneous graphs to address these limitations. HeteroKGRep is a multi-step framework that first generates a similarity graph from hierarchical concept relations. It then applies SMOTE over-sampling to address class imbalance before generating node sequences using a heterogeneous graph neural network. Drug and disease embeddings are extracted from the network and used for prediction. We evaluated HeteroKGRep on a graph containing biomedical concepts and relations from ontologies, pathways and literature. It achieved state-of-the-art performance with 99% accuracy, 95% AUC ROC and 94% average precision on predicting repurposing opportunities. Compared to existing homogeneous approaches, HeteroKGRep leverages diverse knowledge sources to enrich representation learning. Based on heterogeneous graphs, HeteroKGRep can discover new drug-desease associations, leveraging de novo drug development. This work establishes a promising new paradigm for knowledge-guided drug repositioning using multimodal biomedical data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600970 | PMC |
http://dx.doi.org/10.1016/j.knosys.2024.112638 | DOI Listing |
Front Pharmacol
December 2024
Syreon Research Institute, Budapest, Hungary.
Background: Non-adherence to medication remains a persistent and significant challenge, with profound implications for patient outcomes and the long-term sustainability of healthcare systems. Two decades ago, the World Health Organization (WHO) dedicated its seminal report to adherence to long-term therapies, catalysing notable changes that advanced both research and practice in medication adherence. The aim of this paper was to identify the most important progress made over the last 2 decades in medication adherence management and to initiate a discussion on future objectives, suggesting priority targets for the next 20 years.
View Article and Find Full Text PDFHealth Inf Sci Syst
December 2025
Division of Software, Yonsei University, Mirae Campus, Yeonsedae-gil 1, Wonju-si, 26493 Gangwon-do Korea.
Purpose: Drug repositioning, a strategy that repurposes already-approved drugs for novel therapeutic applications, provides a faster and more cost-effective alternative to traditional drug discovery. Network-based models have been adopted by many computational methodologies, especially those that use graph neural networks to predict drug-disease associations. However, these techniques frequently overlook the quality of the input network, which is a critical factor for achieving accurate predictions.
View Article and Find Full Text PDFCancer Med
January 2025
Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Purpose: Upper tract urothelial carcinoma (UTUC) presents a higher incidence rate in Taiwan compared to Western societies. The aim of this study is to investigate the potential of metformin in improving survival outcomes for patients with UTUC in Taiwan.
Material And Methods: This retrospective study included 940 patients with UTUC and type 2 diabetes from the Taiwan UTUC Collaboration Group, spanning 21 hospitals from July 1988 to September 2023.
Yakugaku Zasshi
January 2025
Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences.
Pre-eclampsia, a type of hypertensive disorders of pregnancy (HDP), is characterized by hypertension and organ dysfunction that develops or worsens after 20 weeks of gestation. Although symptomatic management using antihypertensive medications has been adopted, definitive treatments other than pregnancy termination remain unavailable to halt disease progression. Research on heme oxygenase (HO)-1, a molecule with anti-inflammatory and antioxidative properties, has shown that a pharmacological increase in placental HO-1 expression and activity may ameliorate this condition; therefore, HO-1 is a promising therapeutic target for this disorder.
View Article and Find Full Text PDFBiol Pharm Bull
January 2025
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.
As unexpected adverse events and successful drug repositioning have shown, drug effects are complex and include aspects not recognized by developers. How can we understand these unrecognized drug effects? Drug effects can be numerized by encompassing biological responses to drugs. For instance, the transcriptome data of cultured cells and toxicopathological images of mice treated with a compound represent the effects of the compound in vitro and in vivo, respectively.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!